Suven Life Sciences: Phase-1 trial of SUVN-I6107 successful

Suven Life Sciences announced the successful completion of its Phase-1 first-in-human clinical study for SUVN-I6107, a novel muscarinic M1 positive allosteric modulator (M1-PAM) for CNS disorders. The study demonstrated a favorable safety profile with no dose-limiting toxicities and achieved projected therapeutic exposures. Key findings include robust pharmacodynamic activity showing CNS effects, no significant PK differences between sexes, and no relevant impact of food on PK. These positive results support the advancement of SUVN-I6107 into Phase-2 clinical development, expanding Suven's neuroscience pipeline.